Ernexa Therapeutics Inc. Impairment of Intangible Assets, Finite-lived
Ernexa Therapeutics Inc. (ERNA) reported Impairment of Intangible Assets, Finite-lived of $295.00 thousand for the 12-month period ending 2015-12-31, per its 10-K filed 2016-03-15.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsFinitelived · last filed 2016-03-15
- Ernexa Therapeutics Inc. impairment of intangible assets, finite-lived for the quarter ending 2015-12-31 was $0.00, a 100.00% decline year-over-year.
- Ernexa Therapeutics Inc. impairment of intangible assets, finite-lived for the quarter ending 2015-09-30 was $0.00.
- Ernexa Therapeutics Inc. impairment of intangible assets, finite-lived for the quarter ending 2015-06-30 was $295.00K, a 53.83% decline year-over-year.
- Ernexa Therapeutics Inc. impairment of intangible assets, finite-lived for the quarter ending 2015-03-31 was $0.00.
- Ernexa Therapeutics Inc. impairment of intangible assets, finite-lived for fiscal 2015 was $295.00K, a 55.84% decline from fiscal 2014.
- Ernexa Therapeutics Inc. impairment of intangible assets, finite-lived for fiscal 2014 was $668.00K.
| Period end | Impairment of Intangible Assets, Finite-lived 3 month | Impairment of Intangible Assets, Finite-lived 6 month | Impairment of Intangible Assets, Finite-lived 9 month | Impairment of Intangible Assets, Finite-lived 12 month |
|---|---|---|---|---|
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | $0.00 derived: sum of 2 quarters · filed 2016-03-15 | $295.00K derived: sum of 3 quarters · filed 2016-03-15 | $295.00K 10-K · filed 2016-03-15 |
| 2015-09-30 | $0.00 10-Q · filed 2015-11-09 | $295.00K derived: sum of 2 quarters · filed 2015-11-09 | $295.00K 10-Q · filed 2015-11-09 | $302.00K derived: sum of 4 quarters · filed 2016-03-15 |
| 2015-06-30 | $295.00K 10-Q · filed 2015-08-10 | $295.00K 10-Q · filed 2015-08-10 | $302.00K derived: sum of 3 quarters · filed 2016-03-15 | $302.00K derived: sum of 4 quarters · filed 2016-03-15 |
| 2015-03-31 | $0.00 derived: 10-K 12 month − 3 quarters · filed 2016-03-15 | $7.00K derived: sum of 2 quarters · filed 2016-03-15 | $7.00K derived: sum of 3 quarters · filed 2016-03-15 | $646.00K derived: sum of 4 quarters · filed 2016-03-15 |
| 2014-12-31 | $7.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | $7.00K derived: sum of 2 quarters · filed 2016-03-15 | $646.00K derived: sum of 3 quarters · filed 2016-03-15 | $668.00K 10-K · filed 2016-03-15 |
| 2014-09-30 | $0.00 10-Q · filed 2015-11-09 | $639.00K derived: sum of 2 quarters · filed 2015-11-09 | $661.00K 10-Q · filed 2015-11-09 | |
| 2014-06-30 | $639.00K 10-Q · filed 2015-08-10 | $661.00K 10-Q · filed 2015-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |